CAJ | 학술논문

目的：观察重组人血管内皮抑制素（恩度）联合顺铂治疗晚期非小细胞肺癌（ NSCLC ）恶性胸腔积液的临床疗效和不良反应。方法90例晚期NSCLC合并恶性胸腔积液患者随机分为联合组（45例）和顺铂组（45例），联合组胸腔内注入恩度45 mg＋顺铂40 mg／m2，2次／周，连续3周；顺铂组单用顺铂40 mg／m2胸腔灌注治疗，2次／周，连续3周。评价近期疗效、生活质量（ QOL）和不良反应。结果联合组客观有效率（ RR）82．22％；顺铂组为51．11％（ P＜0．05）；联合组QOL改善有36例（80．00％），顺铂组为20例（44．44％）（P＜0．05）。2组不良反应比较差异无统计学意义。结论恩度联合顺铂治疗晚期NSCLC胸腔积液疗效显著，可明显改善患者的生活质量，且不良反应小。
목적：관찰중조인혈관내피억제소（은도）연합순박치료만기비소세포폐암（ NSCLC ）악성흉강적액적림상료효화불량반응。방법90례만기NSCLC합병악성흉강적액환자수궤분위연합조（45례）화순박조（45례），연합조흉강내주입은도45 mg＋순박40 mg／m2，2차／주，련속3주；순박조단용순박40 mg／m2흉강관주치료，2차／주，련속3주。평개근기료효、생활질량（ QOL）화불량반응。결과연합조객관유효솔（ RR）82．22％；순박조위51．11％（ P＜0．05）；연합조QOL개선유36례（80．00％），순박조위20례（44．44％）（P＜0．05）。2조불량반응비교차이무통계학의의。결론은도연합순박치료만기NSCLC흉강적액료효현저，가명현개선환자적생활질량，차불량반응소。
Objective To observe the clinical efficacy and adverse reactions of recombinant human endostatin ( en-dostar) combined with cisdiammi dichloride platinum (cDDP) in the treatment of advanced non-small cell lung cancer(NSCLC) patients with malignant pleural effusion .Methods 90 cases of advanced NSCLC patients with malignant pleural effusion were randomly divided into the combination group (endostar combined with cDDP)and the cDDP group,each with 45 cases.The combi-nation group was performed pleural perfusion of endostar 45 mg and cDDP 40 mg/m2 ,twice a week for 3 weeks .The control group was only given pleural perfusion of cDDP 40 mg/m2,twice a week for 3 weeks.The efficacy,quality of life(QOL),and adverse re-actions were evaluated.Results The recovery rate(RR)of the combination group was 82.22%,and 51.11% for the control group(P<0.05).36(80.00%)patients in the combination group reported improved QOL ,while there were only 20(44.44%)in the control group(P<0.05).The differences of adverse reactions in both groups had no statistical significance .Conclusion Pleural perfusion of endostar combined with cDDP is a safe and feasible way to treat advanced NSCLC patients with malignantpleural effusion,it can improve QOL of patients with mild adverse reactions .